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Abstract
The ability to extrapolate nutritional intervention data from experimental rodent models
to humans requires standardization of dietary design. The inability to translate the level of
nutrients from animal models to humans has contributed to contradictory findings between
species. It is hypothesized that dietary linoleic acid (LA) promotes chronic and acute diseases by
enriching tissues with arachidonic acid (AA), its downstream metabolite. However, levels of LA
in rodent diets are notoriously erratic making interspecies comparisons unreliable. Therefore, the
ability to extrapolate the biological effects of dietary LA from experimental rodents to humans
necessitates an allometric scaling model that is rooted within a human equivalent context. To
determine the physiological effect of dietary LA on tissue AA, a mathematical model for
extrapolating nutrients based on energy was designed to mimic human equivalent doses.
C57BL/6J mice were divided into 9 groups fed a background diet equivalent to that of the US
diet (including LA, ALA, AA, EPA, DHA) with supplemental doses of LA (up to 2.3x) or AA
(up to 5x). Changes in the phospholipid fatty acid compositions were monitored in plasma and
erythrocytes and compared to data from humans supplemented with equivalent doses of LA or
AA. Increasing dietary LA had little effect on tissue AA, while supplementing diets with AA
significantly increased tissue AA levels, recapitulating results from human trials. Thus,
interspecies comparisons for dietary LA between rodents and humans can be achieved when
rodents are provided human equivalent doses based on differences in metabolic activity as
defined by energy consumption.

List of abbreviations:
ALA, alpha-linolenic acid; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid
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Introduction
The consumption of dietary fat and the incidence of cardiovascular disease, inflammation,
and cancer have been evolving concepts of nutrition since Burr and Burr‟s 1929 discovery of fat
as a essential component of the diet [1]. Various animal studies have examined the role of
polyunsaturated fatty acids (PUFAs), particularly n-6 fatty acids, for their functional role in
tissues and for their implication in disease prevention. However, the ability to extrapolate
nutritional intervention data from experimental rodent models to humans remains a multifaceted
problem. The inability to translate the level of nutrients from animals to humans along with the
lack of standardization in dietary design, have contributed to contradictory results often observed
between the two. Specifically, inappropriate background doses of linoleic acid (LA, 18:2n-6)
have been proposed to benefit cancer, inflammation, and atherosclerosis [2-5]. Current research
suggests a growing concern that overconsumption of LA, the precursor to arachidonic acid (AA,
20:4 n-6), is responsible for the increased predisposition to disease [6-7]. This study intends to
verify a mathematical model for formulating rodent diets that will more closely mimic the typical
human diet and human responses. The following questions will be addressed:

1. What is the biological impact of n-6 fatty acid, LA, as a metabolic precursor for AA?
2. What methodological improvements can be made in relevant dosing of n-6 fatty acids in rodent
studies that will allow for standardization of dosing between animal models and human data
across different research designs?
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Part I

Overview
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Abstract
In the absence of other n-6 PUFAs (including dietary AA), dietary LA is the sole
contributor to tissue AA. Following consumption, LA is desaturated and elongated to AA. It is
hypothesized that robust downstream metabolism of LA to AA benefits cancer, inflammation,
and atherosclerosis; however dietary composition and dosing of n-6 PUFAs among animal
research is highly variable. As such, rodent dietary design is of immense importance in the field
of nutrition research, not only in determining this relationship, but as a way to assess the
translational ability of individual dietary constituents, through appropriate dosing of nutrients, to
physiological effects observed in humans consuming similar levels of nutrients. Currently, there
have been only a few attempts to standardize the levels of nutrients in a rodent diet to have
human relevance. A random search of the literature supports this lack of standardization in
dietary design and dosing of LA. The concern governing the heterogeneity of rodent dietary
designs ultimately makes it challenging to extrapolate the findings to humans with a level of
confidence. Therefore, investigating appropriate scaling measures for interspecies comparisons is
critical. Establishing a model that provides standardization and a hierarchical approach to
designing diets seems pressing. If the ultimate goal is to translate findings to humans, identifying
allometric scaling models is fundamental for all disciplines.
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REVIEW OF THE LITERATURE
1.0 Overview of Omega-6 Fatty Acids
Description
Fatty acids are denoted by straight chain hydrocarbons possessing a carboxyl (COOH) group
at one end and a methyl (CH3) group at the other. N-6 fatty acids are polyunsaturated lipid
compounds that consist of a hydrocarbon skeleton and classified by the location of the first
double bond on the sixth carbon from the methyl end [8]. Each double bond is separated by a
methyl group, a process termed methylene-interrupted, which provides structural stability but the
potential for oxidation. LA and AA are the two predominant n-6 PUFAs. Since humans lack the
ability to synthesize fatty acids with double bonds greater than the ninth carbon from the
carboxyl end; these PUFAs are considered essential, indispensible, and must be included in the
diet [8-9]. Additionally, LA is an essential component of ceramides involved in maintenance of
the transdermal water barrier of the epidermis and both LA and AA are required as precursors for
eicosanoid production [10-11].

Molecular Structure

arachidonic acid (20:4n-6)

Figure 1. The molecular structure of LA and AA, derived from Laura Jones‟s Thesis, 2005.
4

Dietary Sources
Foods rich in LA include most vegetable oils (i.e., sunflower, safflower, evening
primrose, sesame, corn and soy) [8, 12], animal products (i.e., chicken, pork, steak) and dairy
products (i.e., eggs, cheese) [13]. AA is found exclusively in animal products (i.e., beef ribeye,
chicken, eggs, pork loin, turkey, fish) [14]. A comparison of food sources high in LA and AA is
depicted in (Table 1).

Western Consumption of LA
Dietary LA is the most abundant PUFA in Western consumption [13-15]. Median intakes
of LA are held respectively between 11–17 g/day for women and men (contributing to ~4-10%
energy based on a 2,000 kcal/d diet) [15-17]. Notably, LA recommendations are 10 to 100 times
higher than alpha-linolenic acid (ALA) and other essential long-chain fatty acids [15], (Table 2).
Hence, LA represents 90% of n-6 fatty acids in the Western diet [12]. The rise in LA-containing
oils (i.e., corn, sunflower, safflower, soybean) and the shift in the n-6 to n-3 ratio mirrors the
growth of the innovative vegetable industry [18].

Table 1. Dietary sources of linoleic acid and arachidonic acid [14]
Food Item

Linoleic acid

Arachidonic acid

mg fatty acid/100g cooked food
Chicken thigh
Chicken breast
Egg (whole)
Beef rib eye
Canned tuna

838 ± 27
272 ± 17
1884 ± 183
320 ± 51
25 ± 2

121 ± 6
83 ± 8
239 ± 21
77 ± 14
33 ± 4
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LA Deficiency
The severity of dermatitis, skin barrier dysfunction, and cutaneous inflammation are
associated with the depletion of essential n-6 PUFAs at levels required in the diet; observed in
both rodent and human studies [1, 19]. Dietary consumption of LA at 1-3% of energy is
sufficient for AA synthesis and turnover [12, 20]. Biochemical and dysfunctional consequences
of n-6 PUFA deprivation in rodents under normal n-3 PUFA concentrations, further explain the
essentiality in a tissue specific manner (i.e. reductions in brain, heart, liver, etc) [21].
Interestingly, n-6 PUFA deprivation is associated with increased concentrations of n-3 PUFAs
and monounsaturated fatty acids (MUFAs) for maintenance of adequate membrane fluidity and
body function [21]. Membrane saturation requirements of both n-3 and n-6 PUFAs are therefore
essential for establishing an appropriate dietary design in both humans and rodents.

Availability to Human Tissues
Dietary consumption of LA above 2-3% of energy in humans is not reportedly
accompanied by an increase in AA plasma/serum and erythrocytes lipid levels [12, 22-25]. In
human peripheral tissues, increasing dietary LA from 4% to 18% of energy resulted in lower
levels of AA in the cholesterol esters and phospholipid fractions of hyperlipemic subjects [26].
Adam and colleagues found significant increases in LA plasma cholesterol esters and HDLphosphatidylcholine when LA was supplemented up to 20% of energy compared to a fat-free
diet. Tissue levels of AA significantly decreased in the high dietary LA groups (4% and 20% of
energy) while increasing in the fat-free group [20]. These results are indicative of the influential
power of dietary LA to increase tissue LA, but not AA in this human study. Interestingly, neither
group given differential levels of dietary LA (4% and 20% of energy) increased prostaglandin
6

(PG) synthesis [20]. These findings are in agreement with the concept that desaturation of fatty
acids regulates cell fluidity and does not favor increased PG formation via the AA cascade when
fed adequate amounts of LA (at least 1-3% of energy) [12]. Nonetheless, the relationship
between LA and AA in rodents has yet to mimic the responses observed in humans. A
perspective look at LA in the diet of both rodent and human studies may provide more of a
consensus on the biological effects of LA-derived foods and the relationship to acute and chronic
diseases.

Table 2. Suggested adequate intake and recommended intakes of n-6 polyunsaturated fatty
acids versus current estimated consumption in the United States [27]
Linoleic Acid
(LA) 18:2n-6

Linolenic Acid
(ALA) 18:3n-3

6.4% energy
17 g/d @ 2400 kcal
12 g/d @ 1700 kcal

0.6% energy
1.6 g/d @ 2400 kcal
1.1 g/d @ 2400 kcal

5-8% energy
~15 g/d @ 2000 kcal
6.3% energy
14 g/d @ 2000 kcal

0.75% energy
~1.7 g/d @ 2000 kcal
0.75% energy
1.7 g/d @ 2000 kcal

National Academy of Sciences
(AI)
(DRI, 2002)
Men
Women
Recommendations [27]
All adults
Current Mean Estimated Intakes
[28]
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Western Consumption of AA
AA is arguably the most important fatty acid associated with membrane phospholipids
and is involved in eicosanoid production, and cellular proliferation and differentiation [14-15].
While dietary LA is a contributor to tissue AA, variations in LA consumption, specifically LA
intakes above 2% of calories in humans, were reported to have only minimal alterations on
changes in the content of AA in phospholipids of human neutrophils [24]. Additional human
clinical trials report dietary variations of LA from (3%-20% of energy) did not significantly
increase tissue AA concentration [22, 25]. A human tracer study that examined median fractional
turnover rate of LA, found as little as 0.3% to 0.6% of LA was converted to AA [29]. In rodents,
the in vivo conversion of supplemented C18 fatty acids (i.e., LA, ALA) to downstream endproducts (i.e., AA, DHA), measured by stable isotopes, was found less efficient when compared
to C20 fatty acids, possibly indicating the control of ∆-6 desaturase in regulating metabolic
activity when dietary PUFA intake is high [30].
The consumption of AA-derived foods, however, significantly impacts tissue AA
concentrations in both animal studies [31-33] and human trials [34]. Estimated median intake of
AA in humans is 100-500 mg/day (~0.9 % energy), respectively, notably lower than LA. Due to
the unreliability of food composition databases for highly unsaturated fatty acids (HUFAs), the
accuracy of daily AA intake is still unclear [13].
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Digestion, Absorption, and Transport
The composition of cellular membranes are regulated by both genetic and environmental
factors, in particular, dietary fat profiles [35]. Dietary n-6 fatty acids are consumed in the form of
triglycerides and phospholipids found in food. The majority of dietary lipids ~98% are found as
triacylglycerols (TAG) which contain three fatty acids esterified to a glycerol backbone [36]. N-6
fatty acids, LA and AA, are located in the sn-2 position of the triglyceride molecule [11]. While
these fatty acids have a specialized location on the TAG they still follow the same digestion,
absorption, and transport as all other lipid components.
Digestion of dietary lipids begins in the stomach where short and medium chain fatty
acids are hydrolyzed by gastric lipase, an enzyme secreted by the gastric mucosa [36-37].
Gastric lipase works in the stomach under acidic conditions to cleave medium chain fatty acids
into diacylglycerol (DAG) and free fatty acids (FFAs) [37]. Some short and medium chain fatty
acids can be readily absorbed through the stomach, while longer fatty acids must be broken down
in the small intestine. Fat digestion continues through the action of pancreatic lipase and
colipase at the interface of the oil and aqueous phase [37]. Working mainly on the sn-1 and sn-3
position of the TAG, pancreatic lipase releases 2-monoacylglycerol (MAG) and FFAs, important
for further emulsion by the action of bile salts [37]. The presence of bile in the lumen of the
intestine increases the solubility of lipolytic products in the aqueous intestine to emulsify the
intestinal contents for formation of micelles [38]. The components of the micelle are transported
into the enterocyte for reesterification into TAGs, phospholipids, and cholesterol [36].
Translocation across the membrane occurs by both passive diffusion and carrier-mediated
transfer [38]. After the reassembly within the enterocyte, triglycerides and phospholipids are
combined with apolipoproteins to form chylomicrons which can then enter the lymphatic
9

circulation as TAG-rich lipoproteins. Once in the circulation, lipoprotein lipase works similarly
to pancreatic lipase, in that it hydrolyzes the TAG-rich lipoproteins into one monoacylglycerol
and two FFAs for tissue utilization [36]. Glycerol and chylomicron remnants are subsequently
cleaved by the liver.

Biomarkers of Dietary Fat
Lipid metabolism is highly altered by variations in dietary intake that work to maintain a
stable membrane composition. Daily fluctuations in fatty acids reflect the competitive nature of
n-3 and n-6 PUFAs, thus providing useful information about average tissue maintenance [39].
The assessment for fatty acid composition in various compartments such as adipose tissue (longterm), erythrocytes (medium-term), and plasma or serum (short-term) enable stable readings over
a given period of time [40]. A common fatty acid biomarker for human and rodent studies is the
erythrocyte (RBC) membrane. RBC membranes vary with environmental factors, oxidative
stress, and diet [41]. It is held that erythrocyte fatty acid measurements more accurately correlate
with dietary intake than do measurements of serum FA‟s [41]. While RBC turnover (120 day
lifespan) provides a better marker of long-term fat intake compared to plasma, phospholipids,
TAGs, this view is not consistently held across all research [42]. Alternatively, plasma lipid
fractions provide the most accurate dietary reflection of short-term fatty acids, particularly those
fatty acids after a meal [42]. It has been observed that maximal saturation of RBCs and plasma
TAGs was achieved within 14 days [42]. This is important in determining the length of a human
or animal dietary intervention study to ensure that fatty acids have reached their maximal
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threshold in tissues. Additionally, choosing the most appropriate biomarker accessible for
interspecies comparisons is an essential component of experimental design.

1.1 Conversion of LA to Downstream Metabolites
It is well established that mammals lack the ability to desaturate fatty acyl chains beyond
the ∆ 9 carbon, therefore making consumption of precursor long-chain fatty acids, such as LA,
an essential component of the diet [43]. Following consumption, LA can participate in
oxidization, incorporation into membrane phospholipids, storage in TAGs, or convert to longchain metabolites [13]. PUFAs, both n-3 and n-6 are synthesized by membrane-bound desaturase
families; ∆-6 and ∆-5 desaturases [43]. The conversion of LA to its downstream metabolites is
first catalyzed by ∆-6 desaturase, also known as the rate-limiting step for enzymatic PUFA
biosynthesis [35]. All desaturases require molecular oxygen for addition of intermittent double
bonds along the substrate in a way that maintains the methylene-interrupted distribution [44].
Elongases which are enzymes responsible for adding two carbons to the carboxylic end of the
fatty acid, help regulate metabolic fate and degree of unsaturation. The ∆-5 desaturase which
places a double bond at the ∆-5 position of the 20-carbon fatty acid is responsible for the final
conversion of LA to its preferred form as AA in tissues [43]. In humans, further desaturation of
AA is limited by the body‟s preference to maintain a precise quantity of AA in cells and tissues
[10] (Figure 1).
The majority of LA conversion to long-chain metabolites, with the help of elongases and
desaturases, is presumed to take place in the endoplasmic reticulum [45]. However, biosynthesis
of PUFAs is indeed a coupled process between the endoplasmic reticulum and β-oxidation in
11

peroxisomes during final conversion steps [46-47]. Intermediates can either be incorporated into
phospholipids or become the substrates for further downstream conversion [16]. LA may
additionally participate in low-density lipoprotein (LDL) clearance and decreased LDL
production important in maintaining adequate cholesterol levels [27]. Importantly, LA appears to
hold a membrane “threshold” requirement affected by various environmental (i.e. diet) and
genetic factors (as reviewed by [27]). Furthermore, exaggeration of plasma and tissue fatty acid
composition of specific fatty acids (i.e., AA, EPA, DHA) may result if LA levels fall below the
threshold of essentiality (as reviewed by [27]). Additionally, LA and AA are important for
eicosanoid signaling, pinocytosis, ion channel modulation, and gene expression regulation [43].

12

Linoleic Acid (18:2 n-6)
∆-6 Desaturase
Gamma Linolenic Acid (18:3 n-6)
Elongase
Dihomo Gamma Linolenic Acid (20:3 n-6)
∆-5 Desaturase
Arachidonic Acid (20:4 n-6)
Equilibrium in
Mammals

Elongase
Docosatetraenoic Acid (22:4 n-6)
Elongase
Tetracosatetraenoic Acid (24:4 n-6)
∆-6 Desaturase
Tetracosapentaenoic Acid (24:5 n-6)

Peroxisomal RetroConversion
Docosapentaenoic Acid (22:5 n-6)

Figure 2. Omega-6 fatty acid metabolism
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Metabolism of Arachidonic Acid
AA is considered one of the most abundant PUFAs involved in membrane phospholipids
and production of eicosanoids [33]. The initial step in eicosanoid synthesis is translocation of
phospholipase A2 (PLA2) to the cell membrane by a receptor-mediated influx of Ca2+ ions [48].
Hydrolysis by phospholipase A2 (PLA2) cleaves the ester bond of AA at the sn-2 position,
generating a FFA and a lysophospholipid [49]. Free AA is a precursor for synthesis of PGs in the
conversion through cyclooxgensase (COX) and lipoxygenase (LOX) pathways to generate
eicosanoids (i.e. PGs and leukotrienes) involved in the inflammatory process [8, 48-49] (Figure
2). An imbalance between high intakes of LA and eicosanoid production through AA
metabolism has been proposed to promote atherosclerosis, tumor growth, and immune-related
pathologies [50]. Therefore, targeting tissue AA content for regulation of eicosanoid expression
is a growing topic of interest [10, 33]. Like LA, there appears to be a membrane “threshold”
requirement of AA in tissues [15]. However, dietary alterations of LA to control AA metabolism,
as proposed by many authors, would require drastic changes in the Western diet (i.e. elimination
of nearly all animal and plant products) [15]. Furthermore, dietary LA within the context of a
typical human diet has not been found to increase the risk of acute and chronic disease states
through AA metabolism [15, 51-52].
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Arachidonic Acid (20:4n-6)

Cycloxygenases
(i.e. COX-1, COX-2)

Eicosanoids (i.e.
prostaglandins,
thromboxanes)

Lipoxygenases
(i.e. 5-LOX, 12LOX, 15-LOX-1)
Cancer

Inflammation

HETE
Leukotrienes

CVD
Platelet
Aggregation

Figure 3. Downstream metabolism of AA
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1.2 Overconsumption Concerns Governing LA
The role of n-6 PUFAs in disease prevention is an unrelenting topic of interest and
controversy. Relative changes in the course of evolution have been shaped by a variety of genetic
and environmental changes impacting the modern-day diet. Paleolithic dietary habits (45,000
years ago) were comprised mainly of fish, wild plants, and nuts and seeds that were much lower
in total fat than the current Western diet; however, there is no available data on the health status
of these predecessors [16, 28]. Moreover, the ratio of n-6 and n-3 fatty acids was once thought to
be 1:1 [28, 53-54]. The increase in technological advancements and the food supply has shifted
this ratio toward an increased consumption of n-6 fatty acids at the expense of n-3; proposed to
be 15:1 and 20:1 [6, 11, 16, 54]. This shift, however, mirrors the growth of the innovative
vegetable oil industry [28]. In all actuality, the mean ratio of n-6 to n-3 fatty acids in the United
States is held respectively at ~9.8:1 [28]. Since it has been proposed that dietary fatty acids are a
reflection of membrane fatty acid composition, considerable speculation of the n-6 to n-3 ratio
have arisen for implication in various diseases [53]. The concern of increased dietary n-6 PUFAs
lies in the production of AA, a central pathway for eicosanoid synthesis. Simopoulos and
colleagues propose “a diet rich in omega-6 fatty acids shifts the physiological state to one that is
prothrombotic and proaggregatory, with increases in blood viscosity, vasospasm, and
vasoconstriction and decreases in bleeding time [54].” The common term for n-6 PUFAs, as
consistently noted by many authors, is seamlessly interchanged with dietary LA. This generic
term, while correct, negates the differential tissue specific effects of individual n-6 PUFA
metabolites.
Higher dietary n-6 PUFAs is suggestive of greater antagonist effect on n-3 PUFA
metabolism of α-linolenic acid (ALA) and reduced cardioprotection [54-55]. Additional
16

arguments propose lower LA intakes will produce a higher n-3 index for protection against
coronary heart disease (CHD) [56] by reducing the exposure of eicosanoid metabolism and
inflammation [55]. However, data strongly suggests a direct inverse association of decreased LA
and increased CHD risk [57]. Interestingly, a study by Riediger and colleagues found a diet high
in n-6 PUFAs, relative to n-3, actually reduced plasma TG levels comparable to baseline values
in mice [58]. Nonetheless, membrane fatty acid composition is influenced by exogenous fatty
acids and the balance of substrates in the diet [55, 59].
While the n-6 to n-3 ratio has indeed increased, targeting the consumption of LA may not
be the answer. Kris-Etherton and colleagues argue that a variation in LA intake does not
substantially affect tissue AA levels in humans, with only ~0.2% dietary LA actually converted
to AA in tissues [60-61]. Additional support from rodents, found dietary LA to have little effect
on altering AA hepatic phospholipids compared to the supplementation of dietary AA which
significantly enriched AA tissue levels [62]. One possible explanation of dietary AA
accumulation in mice may be a result of reduced oxidation to CO2 ,with only 14% compared to
42% from dietary LA [62] or that the accumulation of dietary AA in mice may be subject to a
dietary experimental design that lacks one or more essential fatty acids. Nonetheless, the debate
on the overconsumption of LA in both rodent and human studies remains inconclusive.
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1.3 Health Implications
Cardiovascular Health
Dietary profiles may provide one way for assessing the link of PUFA consumption and
optimal heath. The American Heart Association supports an n-6 PUFA intake of at least 5-10%
of energy for heart health (as reviewed by [60]). The „consume less‟ n-6 theory (as reviewed by
[6]) lies in the formation of atherosclerotic plaque initiated by the accumulation of LDL and proinflammatory cytokines that is believed to be driven by the competition of AA and EPA for
metabolic conversion [8]. It is assumed that the link between PUFA consumption and
cardiovascular disease (CVD) lies in eicosanoid regulation [8] and protection from oxidative
damage [63]. While the n-3 index is an important marker for CHD there are other factors that
contribute to cardioprotection [60]. Therefore, the antagonistic role of LA or AA with EPA does
not appear to substantially lower the n-3 index [60]. Clearly this paradigm is complex and often
misinterpreted.
A review of the literature by Harris [57] found most data in favor of increasing dietary
LA to decrease the risk of CHD. In humans, a meta-analysis found that n-6 PUFA intake of 1021% energy reduced the risk of CHD compared to individuals with lower intakes [57]. In fact,
LA is found to be the most potent dietary fatty acid in reducing total cholesterol and LDL levels
[64]. In a human study, feeding 25% of energy from LA over a 5 year span, there was found to
be reduced atherosclerosis with no adverse side effects [65-66]. Salmeron and colleagues report
that women with a mean intake of 7% of energy from LA had a significantly lower risk of type 2
diabetes compared to those consuming less than 4% of energy from LA [67]. There is evidence
of higher LA intakes improving insulin resistance [68] and effectively lowering blood pressure
[69]. While many human studies demonstrate the ineffectiveness of various dietary LA doses to
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significantly increase cardiovascular risk [27, 70], the majority of animal research and several
human researchers continue to advocate the relationship of n-6 PUFAs and increased
susceptibility to disease [6, 50].

Inflammation
Similar to CVD, LA is proposed to have pro-inflammatory activities independent of its
role as a precursor for AA synthesis [71-72]. The lack of consensus on an appropriate biomarker
for inflammation has left many researchers at a loss for concise comparison [17]. Since, LA is a
substrate for two metabolically active oxidation products (i.e. leukotoxin (LT), leukotoxin diol
(LTD)), in vitro treatment of endothelial cells with LA, LT, or LTD was found to promote
oxidative stress responses [73]. This study would imply that LA metabolism, in part, possesses
pro-inflammatory capabilities. The interference of n-6 PUFAs on n-3 PUFA anti-inflammation is
a well explored topic. In a prospective human cohort, it was found that consumption of n-6 fatty
acids did not inhibit the beneficial effects of n-3 PUFAs, and taken together, higher intakes of
both n-6 and n-3 PUFAs were associated with the lowest inflammation [74]. Similarly, a study
by Liou and colleagues found no significant changes in inflammatory markers when comparing
4% to 12% of energy from LA [22]. In fact, Whelan and colleagues report that LA levels were
significantly lower in tissues when AA was included in the diet [33]. Even when LA was
increased by 55%, AA concentrations did not significantly change or significantly impact
eicosanoid production [33].
In addition to assessing LA, dietary AA has been a central focus of the inflammatory
process. Two human studies report no significant effect on inflammatory biomarkers with the
addition of 1200 mg of AA/day maintaining a constant n-3 intake [75] or with the addition of
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700 mg of AA/day [76]. In contrast, it was found that AA at ~2.4% of energy or, 11 grams
respectively, significantly enhanced the production of PGE2 in peritoneal macrophages of
hamsters, similar to the results found in human studies [33]. Therefore, it is perceivable that AA
also holds a specific threshold in tissues that is affected by other fatty acids present in the diet.
Nonetheless, AA consumed at average human intakes of 180 mg/day, respectively, seems
unlikely to create robust inflammatory stress that could potentiate chronic diseases.

Cancer
There is growing concern over the possible link between dietary fat, particularly animal
fat, and cancer (i.e. breast, colon, intestinal, prostate, etc) [77-81]. Epidemiological studies have
observed a linear relationship with increasing dietary fat and incidence of breast and colon
cancer [79]. Like CVD and inflammation, much speculation has been placed on dietary LA
consumption. Rogers and colleagues observed fewer colon tumors in animals fed 28% beef fat
than the controls fed 15% corn oil (~9% energy LA), while Carroll and colleagues similarly
found a lowered incidence of mammary tumors in animals fed beef fat versus corn oil [79, 82].
This would imply the pro-tumorigenic capability of dietary LA in the form of corn oil-based
diets. Additional rodent studies have found the feeding of LA up to 14% of energy promoted the
growth and progression of mammary tumors in mice [5]. However, in a follow-up study, no
significant differences in tumor progression were found between mice fed the 23% corn oil diet
(~14% of energy from LA) and mice fed the 5% corn oil diet (~3% energy of from LA) [83].
Buckman and colleagues demonstrated the direct stimulatory effect of LA (12% of energy) and
oleate on the growth of mammary tumor cells; suggestive of an independent role of unsaturated
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fatty acids and prostaglandin synthesis [2]. Conversely, Hubbard and colleagues found mammary
tumorigenesis was enhanced by LA and was not dependent of oleic acid (18:1n-9) levels [4].
Two opposing roles of LA on mammary tumorigenesis were observed by Lane and colleagues.
In one experiment, 20% corn oil (~12% of energy from LA) induced metastasis, however the
second experiment found that 20% corn oil did not significantly affect mammary tumor
incidence [2]. In examining lipid profiles of rodents fed corn oil, soybean oil, or palm oil, no
consistent changes were observed in mammary tumor carcinogenesis [84]. Overall, the
consensus on LA‟s role in mammary cancer remains inconclusive, most notably due to
differences in experimental design.
The diets of rodents fed 20% menhaden oil (primarily n-3 fatty acids) versus 20% corn
oil (~12% of energy from LA) were associated with significantly reduced pancreatic lesions [3].
Similarly, Roebuck and colleagues found that 20% corn oil (~12% of energy from LA) was
associated with enhanced perimental pancreatic carcinogenesis in rats [85]. The anti-tumorigenic
effect of n-3 PUFAs demonstrated in these studies point to the opposing role of n-6 and n-3
PUFAs as potent oncogenic precursors based on dietary factors alone. While n-3 PUFAs are
known for their anti-inflammatory properties [86-87] , concluding n-6 PUFAs as carcinogenic
promoters based on the doses used in these studies may not be accurate. In order to better
establish the relationship between diet and disease in a rodent model, a properly scaled design
that includes appropriate doses of nutrients, allometrically based on human DRIs, must first be
implemented in the basic design.
The amount of LA in background dietary designs among animal research is highly
variable. As such, the translation of data from rodents to humans of poorly designed
experimental models has contributed to uncertainty among the literature, noted by many of these
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studies. Therefore, designing rodent diets considering allometric scaling factors and the inclusion
of all human equivalent dietary components may better pinpoint LA‟s specific role in
cardiovascular disease, inflammation, and carcinogenesis.
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1.4 Animal Model Research
Rodent Dietary Models
Currently, there are three main rodent diets used by research intervention studies. These diets
include AIN76A: 5% corn oil (CO) (59% LA, 6.6% of energy); AIN93G: 7% soybean oil (SBO)
(54% LA, 8.3% of energy); and AIN93M: 4% SBO (54% LA, 4.8% of energy) [88] (Figure 4).
While these diets do provide most of the essential fatty acids, they appear to be inconsistent in
levels of LA (based on % of energy). This is of particular interest in investigating the proposed
role of LA-derived foods on enhanced risk for chronic and acute diseases. Notably, current
human consumption of LA is held respectively at ~6 % of energy (7-10 % of energy) [10], but
most rodent dietary intervention studies do not use human equivalent LA doses in the
background diet. Rodent dietary designs utilizing an inappropriate dose of LA (i.e. deficient or
excessive) that does not correspond to human consumption or designs lacking all essential fatty
acids may potentially heighten or exaggerate the responses in tissues [10].

8.3

Energy% of LA

10.0
8.0
6.0

6.6

6
4.8

AIN76A
AIN93G
AIN93M

4.0

Human Dose

2.0
0.0

Dietary Models

Figure 4.The discrepancy of LA doses of current rodent diets based on % of energy from LA
compared to a human equivalent dose containing 6% energy from LA.
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Rodent Designs Supplemented with LA
A collection of rodent studies interested in the response of LA supplementation on tissue
fatty acid composition strikingly outline the variability in animal model experimental design
(Figure 5). The array of varying initial and supplemented doses of LA, portray the inconsistency
of animal dietary design. Additionally, the comparison to a human equivalent dose of ~6% of
energy denotes the improper dosing in the background diet for interspecies comparisons. Rucker
and Storms in 2002, propose that direct extrapolation to an adult human based on doses given to
rodents may be in error by a factor of 10 or higher [89]. Consequently, the overestimation of
nutrients for a smaller animal may lead to toxicities when extrapolated to a larger animal [89].
Therefore, using a standard scientific rationale for dosing may provide more consistent translatable
findings.

35
30

Energy % of LA

25
20
15

Initial Dose of LA
Supplemented Dose of LA
Human Dose

10

5
0

Figure 5. Comparison of a human equivalent dose (6% energy from LA) to initial and supplemented
doses of LA in rodent dietary studies.
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Table 3. The comparison of background and supplemented doses of % energy from LA and the rationale
for experimental design are displayed among various rodent dietary studies.
_____________________________________________________________________________________
Rodent Dietary Designs
Study

Supplemented Background Source of
Background Energy% LA
Energy% LA
PUFA

Intended Outcome

Rationale

0

0.009, 0.02, 0.05,
0.10, 0.18, 0.32,
0.61, 1.26, 1.79,
4.87

Fat-Free

To show the influence of various
levels of LA, AA, and ALA esters
upon FA composition in liver
lipids of rats.

Based on previous studies
comparing animals fed fat-free diets
with those fed single levels of
essential fatty acids.

Mohrhauer et al (1963)

0

0.08 up to 0.73
but Supplemented
ALA at differing
ratios

Fat-Free

To compare to a previous study
feeding LA and ALA singly

Intake levels were chosen in the
range of unstated ratios.

Rahm et al (1964)

0

0.28, 0.97, 1.97,
3.87, 7.57, 12.42,
17.26

Fat-Free

Determine the inhibition of
linolenate metabolism by
linoleate.

None

Corn Oil

To demonstrate whether a diet
high in PUFAs (corn oil) would
enhance or promote DMBA
induced mouse mammary
tumorigenesis in mice.

Based the % energy from other
studies showing that high corn oil
diets change the FA composition in
mammary cells.

Mohrhauer et al (1962)

Lane et al (1985)

~5% Fat- Chow Diet (Wayne
6, 24.6 (Based on
Lab Blox)- Distribution not
AIN76A)
indicated

Ip et al (1985)

~20% w/w Synthetic Fat
Diet (~44% en)

4.4, 9.0, 14.3,
26.6

Coconut oil, Corn oil

To determine the requirement of
essential fatty acid for diBased on other studies investigating
methylbenz(a)anthracene-induced
LA as a tumor-promoter.
mammary tumorigenesis.

Roebuck et al (1986)

6 (AIN diet not specified)

2.5, 24.5

Corn oil, Coconut oil

To examine if the effect of high
levels of unsaturated fats
selectively stimulate carcinogeninduced foci.

Previous investigation found the
high fat diets are comparable in
their effects on rat growth of
pancreatic lesions.

To investigate the efficacy of
varying amounts of mehaden oil
and corn oil on colon
carcinogenesis for determination
of optimal dietary levels.

Based on previous studies looking
at the combination of corn oil and
mehaden oil.

To investigate the effect of
different high palm oil diets on
mammary carcinogenesis in
female rats treated with DMBA.

None

Reddy et al (1988)

6 (Based on AIN76A)

Sundram et al (1989)

Rodent Chow (No
specification)

28.9 (CO group),
Corn oil, menhaden oil
Additional groups
(EPA, DHA, AA, LA, oleic
with CO+
acid, palmitic acid)
Menhaden Oil

24.6 (CO group),
23.8 (SBO group)

Corn oil, Soybean oil,
Crude palm oil,
Deodorized palm oil,
Metabisulfite treated
palm oil

To examine whether oleate, when
added to a diet that promotes
Based on studies in which mice
metastasis (12% enLA) would
were fed 12% energy from LA, they
modulate the growth and
observed significantly more tumors.
metastasis of line 4526 mouse
mammary tummors.

Buckman et al (1989)

3 (Purina Mouse Chow)

12

Mainly safflower oil,
Triolein, Coconut oil

N.E. Hubbard et al (1991)

Stock Diet (Purina Mouse
Chow)

2.2, 13.2, 26.4

8:0, 10:0, 12:0, 14:0,
16:0, 16:1n-7, 18:0,
18:1n-7, n-9, 18:2n-6

To test whether increasing the
dietary level of oleic acid can alter
the level of 18:2n-6 -enhanced
metastasis.

Based on a previous study,
suggesting that 12% w/w (26.4%
energy) from LA induced lung
metastasis.

High oleic sunflower,
Tripalmitin, 18:1n-9
(Oleic Acid Ethyl Ester)

To evaluate the effects of dietary
AA on hepatic tissue FA
composition compared to results
with those obtained from matched
animals on LA diets.

Based on previous studies looking
at dietary AA while controlling for
other FA's.

To investigate the use of lipids
Corn oil, 14:0, 16:0, 16:1, with different FA compositions as
18:0, 18:1n-9
a potential fat source for
parenteral and enteral diets.

Oils were selected for their wide
differences in FA compositons. No
rationale for doses.

Whelan et al (1992)

4.4 (Prolab Chow Diet)

7.5

Lokesh et al (1992)

6

12

Rose et al (1993)

6 (Based on AIN76A)

4.4, 17.6, 26.4

Safflower Oil, Coconut
Oil

To determine the effect of 3
Based on previous studies looking
different levels of dietary LA intake
at high -fat diets on the growth of
on the growth of MDA-MB-435
MDA-MB-435 human breast cancer
cancer cells in mammary fat pads
cell line.
of nude mice.

________________________________________________________________________________
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Rodent vs. Man
Comparing rodent data to human clinical trials results in an observable difference. In
comparing the % change of AA with increasing LA (% of energy) between 8 rodent dietary
studies [2, 21, 33, 62, 90-93], delineates the inconsistent response of AA when LA is provided at
doses of 0.73% to 27% of energy (Figure 6). The differences in the background dietary
composition of these 8 rodent models explain the erratic data. The % change in AA plasma
phospholipids with increasing LA (% of energy) in human studies does not appear to portray the
same LA to AA relationship observed in rodents (Figure 7). Data obtained from humans indicate
a weak correlation between both variables. This intriguing finding is indicative of the
disconnection between rodent and human data. The large response on tissue AA fluctuation in
the rodent models is likely the source for heightened fear governing LA conversion to AA in
tissues. This gap in interspecies translation leads to the importance of an established rodent
dietary model. Formulating an appropriate dietary design for comparison to human clinical trials
will hopefully result in more comparable findings.
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Figure 6. Rodent data comparing the % change in AA with increasing LA (% of energy) between
8 studies [2, 21, 33, 62, 90-93]. The data represents an inconsistent response of AA when LA is
provided at doses of 0.73% to 27% of energy. The red triangles indicate a significant value.

Figure 7. Human data comparing the % change in AA (plasma phospholipids) with increasing
LA. The positive dose responsive relationship between LA and AA observed in rodents does not
appear to exist in humans. The red triangles indicate a significant value. Derived from Brian
Rett‟s Thesis, 2011.
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1.5 RELEVANT DOSING FOR ANIMAL MODELS: A SCALING APPROACH
Introduction
An appropriate dietary design in animal models requires proper extrapolation between
species. Supplemental doses in rodent models must meaningfully represent normal consumption
by humans. For proper use of animal models in nutritional interventions, a certain degree of
thoughtfulness should precede the design. If animal models are to truly predict biological
responses in humans, we first must examine the paradigm of interspecies comparison.

History of Allometric Scaling
Basal metabolic rate (BMR) was first proposed for describing allometric relationships
between body mass and metabolic rate of both animals and humans [94]. BMR represents the
minimal cost of living or energy turnover at constant body temperatures [94-95]. In 1838, Sarrus
and Rameaux were the first to suggest a rationale for interspecies comparison. Their proposed
theory, the Surface Law, suggested that heat loss and production based on different-sized species
should be related to surface area rather than body mass [94]. This proportionality of BMR and
surface area raised to the 2/3-power was accepted well into the 20th-century [96]. In 1916, Krogh
suggested an empirical approach whereby BMR was related to a 0.73 power function of body
mass [94-95]. Krogh‟s discovery led Max Kleiber in 1932, to show that metabolic rate is
proportional to its ¾-power not to body weight alone [97]. This theory is based on the following
equation:
M= 70W3/4
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Where M is the metabolic rate in kilocalories per day and W is body mass in kilograms. This
three-quarter power scaling of BMR is a model of comparative physiology well-accepted by
many researchers for its widespread scaling implications [96]. In pursuit of understanding this
power scaling exponent, West et al [98] proposed a set of principles detailed by the process of
natural selection and sustained “hierarchical branching networks.” Scaling variation observed at
intracellular levels and sub-cellular compartments (mitrochondria) tested in mammalian species,
all proposed the quarter-power allometric scaling feature reflecting constraints inherent in
genetics and energy expenditure into circulation [98].
Three-quarter power scaling is one approach for interspecies comparison that may be
implemented into current research of nutritional animal model designs. Currently there is no
clear standardization of nutrient comparisons in animal research. Typical doses are formulated
based on bodyweight or relative doses that maximize the intended results. Therefore, the aim of
this project is to establish a mathematical model for interspecies evaluation, in particular (n-6)
PUFA levels, for appropriate extrapolation to humans. In order to devise a mathematical model
for widespread implementation in research, this model must include several components: it
should linearize the relationship between rodent and human data; should be applicable to the
general range of (n-6) PUFA studies; be tested on its ability to yield similar biological effects in
animal models and humans; and be straightforward to use.
Body weight has previously been used as a nutritional extrapolation approach, but
according to Rucker and Storms, direct extrapolation from a mouse to an adult human may be in
error by a factor of 10 or more [89]. The misunderstanding in human equivalent doses (HED) has
left a gap in allometric dose translation [99]. Therefore, Rucker and colleagues proposed
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interspecies comparison is best expressed as a measure of metabolic body size or food intake
[89]. Rucker‟s point is further supported in homeothermic animals, showing that mineral
requirements are similar across species when expressed as measure of energy intake [89]. With
these findings, we propose a model based on consideration of daily energy consumption in
rodents and humans as a means of dose standardization.

1.6 Implication in Rodent Dietary Design
When designing an experiment it is crucial to establish scientific rationale for experimental
design. If the overall goal of nutritional intervention studies is to translate the results to people, a
standardized diet appropriate for interspecies comparison must be formulated. The following
proposal hopes to provide more consistent findings and a well-recognized background dietary
standard for all research paradigms.
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1.7 Research Objectives
Specific Aims
Dietary fat has been correlated with the incidence of chronic and acute conditions that are
potentially modifiable [63, 100]. More specifically, the concern for n-6 PUFA overconsumption
of LA appears to arise from rodent experimental models that lack appropriate design for
comparison to humans. The primary aim of this study is to address the disconnection between
experimental models for dietary comparison and provide a more suitable model for nutrient
extrapolations between species.
Our overall goal is to formulate a rodent dietary model with an appropriate background
HED of LA that will equate human equivalent responses based on changes in tissue AA. This
dietary framework will provide a comparative model for nutritional interventions and therefore
appropriate translational research. The objective of this application, which is the next step
toward achieving our overall goal, is to determine the level of LA supplementation that will
mimic human equivalent responses based on changes in tissue AA. The central hypothesis,
based on a mathematical model for allometric scaling, will formulate an appropriate dose of LA
based on energy consumption that will equate human equivalent responses. The rationale
underlying the proposed research comes from a preliminary study in our laboratory looking at
dietary supplementation of n-3 fatty acids, α- linolenic acid (ALA) and eicosapentanoeic acid
(EPA) on tissue concentration in rodents. It was found that an increased amount of ALA was
required in the background rodent diet to mimic human responses. When conducting interspecies
comparisons, it was found that scaling nutrients in standardized rodent diets based on differences
in energy intake extrapolated most nutrients to human intakes based on the DRIs. Similarly, the
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same should hold true when testing the mathematical model for allometric scaling on n-6
PUFAs.
We will test our central hypothesis and achieve the overall objects of this application by
pursing the following two specific aims:
1. Determine the extent to which supplementation of HEDs of LA to a human equivalent
background diet will mimic human responses in tissue AA.
Working hypothesis: If the model for allometric scaling is formulated correctly, the
response in rodents should be similar to the responses in humans at equivalent doses.
2. Determine the extent to which supplementation of AA at HEDs to a human equivalent
background diet will mimic human responses in tissue AA.
Working hypothesis: If the model for allometric scaling is formulated correctly the
response in rodents should be similar to the responses in humans at the same dose.

The proposed research is innovative because there is currently no standardization in
rodent dietary models or a precise scientific rationale for experimental design. We expect this
approach to demonstrate that: 1) the mathematical model for interspecies allometric scaling
appropriately equates human equivalent responses and 2) rodent diets should be based on
differences in energy consumption. Application of this knowledge is expected to provide
translational research for interspecies comparison.
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Abstract
It is hypothesized that dietary linoleic acid (LA) promotes chronic and acute diseases by
enriching tissues with arachidonic acid (AA), its downstream metabolite. However, levels of LA
in rodent diets are notoriously erratic making interspecies comparisons unreliable. Therefore, the
ability to extrapolate the biological effects of dietary LA from experimental rodents to humans
necessitates an allometric scaling model that is rooted within a human equivalent context. To
determine the physiological response of dietary LA on tissue AA, a mathematical model for
extrapolating nutrients based on energy was designed to mimic human equivalent doses.
C57BL/6J mice were divided into 9 groups fed a background diet equivalent to that of the US
diet with supplemental doses of LA or AA. Changes in the phospholipid fatty acid compositions
were monitored in plasma and erythrocytes and compared to data from humans supplemented
with equivalent doses of LA or AA. Increasing dietary LA had little effect on tissue AA, while
supplementing diets with AA significantly increased tissue AA levels, recapitulating results from
human trials. Thus, interspecies comparisons for dietary LA between rodents and humans can be
achieved when rodents are provided human equivalent doses based on differences in metabolic
activity as defined by energy consumption.

List of abbreviations
AA, arachidonic acid; ALA, alpha-linolenic acid; DHA, docosahexaenoic acid; DRI, dietary
reference intake; EFA, essential fatty acid; EPA, eicosapentaenoic acid; HED, human equivalent
dose; LA, linoleic acid; PUFA, polyunsaturated fatty acid
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Introduction
As surrogates for human inquisition, animal models reside at the core of medical

innovation. Through careful environmental control, these genetically similar models facilitate
therapeutic advancements in the magnitude of human disease. Rodent dietary composition is of
particular interest in the field of nutrition research as it provides a way to assess the translational
ability of individual dietary constituents, through appropriate dosing of nutrients, to
physiological effects observed in humans consuming similar levels of nutrients.
Dietary profiles of n-6 polyunsaturated fatty acid (PUFA), linoleic acid (LA) and the
relationship to chronic and acute diseases, in both rodents and humans, appears to lie in tissue
enrichment of downstream metabolite, arachidonic acid (AA) [1-3]. It is hypothesized that
dietary metabolism of AA produces bioactive compounds called eicosanoids that are positively
correlated with the appreciation of tissue AA [4]. While the relationship of AA and eicosanoids
is well established, the response of dietary LA on changes in tissue levels of AA, within the
context of a human equivalent diet, remains inconclusive.
The inconsistent use of n-3 and n-6 essential fatty acids (EFAs) in the background of
rodent diets is pervasive in the literature [5-10]. These EFAs are important components of the
Western diet and can impact the AA phospholipid pool when absent or provided at insufficient
quantities in the diet. Despite suggestions otherwise, a systematic review of the human literature
reports that increases in dietary LA does not appear to significantly modify AA levels in
phospholipids of plasma/serum or erythrocytes when supplemented to standard Western diets
[11]. Therefore, if precise physiological nutrient translation of fatty acids is desired, it may be
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important for dietary aspects of the rodent model to bear firm resemblance to human dietary
components.
This study was designed to necessitate a standard for allometric scaling in animal dietary
design particularly regarding the relationship of dietary LA and tissue AA. This is the first study
to examine the physiological response of dietary LA provided at human equivalent supplemental
doses within the context of a Western background diet, based on a percentage of energy (i.e.,
metabolic activity), on changes in plasma/serum or erythrocyte AA phospholipids. We further
investigated the potential contribution of dietary AA on tissue AA content within the context of a
Western-type diet. This mathematical model for allometric scaling should better equate
interspecies translation and accommodate the differences in metabolic disparity between rodents
and humans.

2.1

Methods
Animals
Sixty-two C57BL/6J male mice (Harlan Laboratory, Indianapolis, IN), 6-7 weeks of age,

were, randomly assigned to nine dietary groups; 5-7 animals per group housed 2-3 animals per
cage. They were housed in a temperature controlled room with a 12 hr light-dark cycle. Prior to
sacrifice, animals were fasted overnight. All animal procedures were approved by the University
of Tennessee Animal Care and Use Committee in accordance with NIH guidelines.
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Diets
All animals were maintained on a control diet for one week prior to being transferred to
one of the experimental diets or maintained on the control diet. The control diet was based on a
US17 Monsanto diet with slight modifications in macronutrient distributions (Table 1). The diet
was designed to mimic the Western diet with the following distribution (% of energy): protein
16%, carbohydrates 50% and lipids 34% (Research Diets, New Brunswick, NJ) [12]. Within the
lipid fraction, saturated, monounsaturated and polyunsaturated fats were designed to be provided
at 13%, 14% and 7% of energy, respectively. The polyunsaturated fats LA, ALA, AA and
EPA+DHA were provided at 6%, 0.6%, 0.07% and 0.1% of energy, respectively. These levels
are similar to those suggested in the literature for humans on a Western diet [12-13] and/or
supported by the DRIs for median daily intakes [14]. AA and EPA+DHA were provided as ethyl
esters (NuChek Prep, Elysian, MN). Experimental diets remained isocaloric and were formulated
using the control diet as the background diet containing LA at ~6% of energy with additional
adjustments in LA content (-2%, +2%, +4%, +6%, +8% of energy) with the addition (or
subtraction) of sunflower oil (70% w/w LA) at the expense of cocoa butter, palm and trisun oils.
The diets supplemented with AA were adjusted at the expense of cocoa butter.
Water and food were provided ad libitum for 21-25 days. Fresh diets were provided daily
and uneaten food was discarded to minimize oxidation prior to consumption. Fatty acid analysis
of the diets is presented in (Table 2).

Fatty acid analysis
Animals were randomized on a 5 day sacrifice cycle. Following 21-25 days on the
experimental and control diets, 0.5-1.0 ml of whole blood was collected via cardiac puncture
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under anesthesia (isofluorane inhalation) using a tuberculin syringe with a 25 gauge needle
containing an anticoagulant (3.8% trisodium citrate). Whole blood was centrifuged at 660 x g for
4 min at room temperature for separation of plasma and erythrocytes, where each fraction was
subjected to lipid extraction. Three ml of chloroform-methanol (1:2, v/v) were added to each
fraction, and lipids were extracted with chloroform (1 ml) plus saline (1 ml), followed by
chloroform (1 ml) (2x). The pooled chloroform extracts were evaporated and resuspended in a
small amount of chloroform (~25 µL), and phospholipids were separated via thin layer
chromatography (TLC) using HPTLC plates precoated with silica gel 60 (Merck, Darmstadt,
Germany) using a chloroform-methanol (8:1, v/v) solvent system. The phospholipids were
recovered from the TLC plates and saponified in 0.5 N NaOH and in the presence of BF3 in
methanol at 86°C. Fatty acids were extracted with equal volumes of hexane (2x) and evaporated
under nitrogen. Fatty acid methyl esters were resuspended in hexane and analyzed by gas
chromatography with a Hewlett-Packard 5880 gas chromatograph (Rochester, NY) using a DB23
capillary column (0.25 mm x 30 m) (J and W Chromatography, Folsom, OH) with hydrogen as
the carrier gas, with temperature programming from 160°C to 250°C at 3.5°C/min The internal
standard 1,2 diheptadecanoyl-sn-glycero-3-phosphocholine (17:0) (Avanti Polar Lipids,
Alabaster, AL) was added to each sample prior to lipid extraction. The fatty acid methyl esters
were identified by comparing the retention times with those of known standards (NuChek Prep,
Elysian, MN).

Statistical analysis
Phospholipid fatty acid content in plasma and erythrocytes were compared across
treatment groups using a one-way analysis of variance (ANOVA), followed by Tukey‟s Honestly
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Significant Difference (HSD) post-hoc test to determine significant differences between groups.
All data was tested for normality using Kolmogorov-Simimov test (K-S test) and Shaprio-Wilk
tests, homogeneity by Levene‟s Test of Equality of Variance, and for outliers using boxplot tests.
The data was evaluated by SPSS 18 statistical package (University of Tennessee, Knoxville,
TN). Data was considered significant at p < 0.05.

2.2

Results

Food intake and weight gain were not statistically different between dietary groups (data
not shown).

Fatty acid composition of plasma phospholipids.
The composition of oleic acid and LA in plasma phospholipids tended to reflect
differences in dietary levels of these fatty acids; however, much of these effects were not
statistically significant (Table 3). The dietary group with the lowest levels of LA and highest
levels of oleic acid (group 1) had the lowest levels of LA and highest levels of oleic acid in the
plasma phospholipids, respectively. The levels of AA did not change in any of the groups with
increasing or decreasing levels of dietary LA (Table 4). DHA levels were not different among
groups, with the exception of group 5. When AA was supplemented to the diets, tissue AA levels
progressively increased in a dose responsive manner at the expense of LA, but tissue DHA levels
did not change. A summary of the effects of LA and AA supplementation are provided in
(Figure 1 and Figure 2), respectively.
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Fatty acid composition of erythrocyte phospholipids
The composition of oleic acid and LA in the phospholipids of erythrocytes reflected
differences in dietary levels of these fatty acids where LA supplementation significantly
increased LA in the tissues (Table 5 and Figure 3). Levels of dihomo-gamma-linolenic acid
(20:3n-6) and AA were unaffected by changes in dietary LA. Similarly, DHA content in
erythrocytes were unaffected by changes in LA intake. When AA was supplemented in the diets,
tissue AA content progressively increased primarily at the expense of LA, but reductions in
dihomo-gamma-linolenic acid were also observed (Table 6 and Figure 4). DHA levels were not
reduced with increasing levels of dietary AA.

2.3

Discussion
Animal models are not intended to replace humans, but be a substitute that is often better

controlled for and better able to answer narrow research questions that could not be done, on a
practical basis, with humans. A common challenge faced by nutrition researchers who are
interested in interspecies comparisons is identifying an appropriate background diet and
appropriate doses for supplemented nutrients. In order to make these choices, studies have to be
performed that can demonstrate human equivalent responses to ensure translation between
species. Without these fundamental studies, no guidelines can be formulated governing scientific
justification for dosing when extrapolation to humans is desired. Currently, no guidelines exist
for appropriate dosing of dietary PUFAs for experimental models (i.e., mice, rats) as they relate
to humans and their intakes. As such, the overall objective of this research was to determine the
extent to which supplementation of human equivalent doses of LA and AA had on changes in
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tissue AA content within the context of a Western-type diet using a common experimental rodent
model and comparing these results to humans. This is the first known study of its kind.
Interspecies comparisons were pioneered by Max Kleiber where he described the nonlinear relationship between metabolic rate and body mass as it relates to allometric scaling with
interspecies comparisons. This pioneer in the field of animal energetics introduced the concept
that the relationship between metabolic rate and body weight could be linearized with the
following equation: Metabolic rate = a(Body Weight)0.75 (where “a” is a proportionality
constant) [15]. More recently, Rucker and Storms (2002) elegantly described the pitfalls of
using differences in body weight as a means of making interspecies extrapolations for
micronutrients because of these non-linear relationships [16]. They addressed the
appropriateness of several mathematical approaches to extrapolate nutrient intake between mice
and humans and suggested food (energy) intake rather than body weight should be used to
extrapolate nutrients for interspecies comparisons [16-17]. Interestingly, when this concept was
applied to a variety of standardized semi-purified diets (i.e., AIN76A, AIN93G, AIN93M),
extrapolations of the nutrients based on energy differentials mimic human equivalent doses. This
provided the scientific justification for the background diet and doses used in this study.
With this in mind, we generated a “human equivalent” background diet where the
macronutrient composition mimicked that of the human diet when based on energy and
evaluated the impact of dietary LA (4%-14% of energy) and AA (0.08%-1.35% of energy) on
changes in tissue AA levels in plasma and erythrocyte phospholipids. These amounts translate
into human equivalent levels of 9-31 g/d and 0.18-2.7 g/d of LA and AA, respectively, and are
within those ranges reported in the DRIs for humans and/or used in clinical trials [11, 14].
Importantly, as opposed to rodent diets that selectively provide only one or two of the essential
56

fatty acids (EFAs) (i.e., corn oil or soybean oil based diets), our background diet contained all
the major n-6 and n-3 PUFAs found in the human diet (i.e., LA, ALA, AA and long chain n-3
PUFA). This is critical as all of these fatty acids are found in the Western diet and can have an
impact on tissue AA levels. For this reason, there has been great interest placed upon n-6 PUFA
metabolism, particularly when all EFAs are sufficiently provided in the diet at human equivalent
levels.
The rodent model has been the superior target for investigation of specific fatty acids and
downstream metabolites on tissue fatty acid composition since 1963 when Mohrhauer and
Holman explored the metabolism of dietary EFAs [7]. In this classic and highly cited paper,
rodents were initially fed a fat-free diet (i.e. with the exclusion of all EFAs) prior to
supplementation of LA (ethyl linoleate) up to 5% from energy, where a 721% increase in liver
AA composition was observed in the highest doses. Other studies recapitulated these earlier
results when LA was provided to a background diet that lacked nearly all or completely all n-3
and n-6 PUFAs [9-10]. When LA was increased from nearly 0% of energy to 6-7% of energy in
rodents, liver AA composition increased 84-173% [6, 8]. Increasing LA from 6% of energy to
27% of energy (or a human equivalent dose of 59 g/d), resulted in a 134% increase in tissue AA
composition [5]. The addition of LA at supra-physiological doses (i.e., 17.3% of energy) from a
background diet containing 7% LA, increased AA content by 375% when no other EFAs were
provided [10]. However, when more moderate levels of LA were supplemented to a diet
containing human equivalent levels (i.e., 6.6% to 13.2% of energy), AA content in liver
phospholipids increased a modest 6% [8]. Notably, tissues have a requirement for unsaturated
fatty acids for structural function and to help maintain membrane fluidity. When animals are fed
a diet that exclusively contains a single PUFA (i.e., LA), its selective and robust conversion to a
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more highly unsaturated form is not surprising. These findings underscore the differential impact
of dietary LA in rodent diets on changes in tissue AA content when the background diet is
devoid of LA and/or other PUFAs, or providing LA at doses approaching pharmacological
levels.
What is an appropriate background diet in rodents and what is an appropriate dose of LA
that has translational ability to humans? This would be dependent upon the human literature; that
is, what is the effect of LA on changes in tissue AA in individuals consuming a typical Western
diet? The DRI for LA is 12g/d and 17g/d for women and men, respectively (approximately 6%
of energy) [14]. In a recent review of the literature, decreasing LA content in the diet up to 90%
or increasing the levels up to 550% was not associated with changes in AA content in the
phospholipid pools of plasma/serum or erythrocytes [11]. It is not unreasonable to think, that
with a background diet containing LA, ALA, AA, and long-chain n-3 PUFAs (i.e., EPA and
DHA) at typical intakes, modifying LA levels may not influence tissue AA levels in these
populations. Hence, in order to establish a human equitable response of dietary LA on tissue AA
composition in the rodent model, it seems best accomplished when all EFAs are present in the
diet, especially for results that are expected to translate proportionally to humans.
Increasing LA from 0% to 2% of energy replete tissue pools of n-6 PUFAs by increasing
AA phospholipid concentrations [18]. Intake of LA above 2-3% of energy in humans is not
reportedly accompanied by an increase in AA content in plasma or erythrocyte phospholipids
[11, 19-24], results consistent with our data. Poor conversion rates in humans would account for
these results where the estimated fractional conversion of LA to AA in adults was between 0.3%
and 0.6% [25]. In rodents, tracer kinetic analysis demonstrated greater efficiency of C20 fatty
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acids in conversion to downstream end-products relative to C18 precursors [26]. This would
imply that feedback inhibition of ∆-6 desaturase, the rate limiting step in the conversion of LA to
AA, may be responsible. Likewise, the present study reports no significant alteration in
plasma/serum or erythrocyte AA phospholipids at the lowest supplemental dose of LA (4% of
energy) or the highest supplemental dose (14% of energy). These results are supported by prior
rodent dietary studies supplementing LA at similar levels (6.8% and 8.7% of energy) to a
background diet already containing LA (4.5% of energy) [27-28]. Hence, supplementation of
HEDs of LA to a background rodent diet consisting of all EFAs found in the human diet,
(including LA and AA) more accurately correspond to the changes in tissue fatty acid
composition of AA in humans consuming similar levels [11, 19-21, 24].
Additionally, our data demonstrates the observable inverse relationship of dietary AA on
changes in tissue LA within the rodent model. When AA was supplemented to rodents
consuming a Western-like diet, tissue AA content increased in a dose dependent manner,
suggesting the lack of changes with LA supplementation was not due to saturation of AA in the
phospholipid pools analyzed. Likewise, when dietary AA was provided to rodents (mice,
hamsters) at 1.5-4% of energy, AA content in hepatic phospholipids increased 21-80%; [12, 2729]. Similar results were observed in intestines, macrophages, lung, heart, spleen, kidneys, testes
and platelets [12, 27-28]. These results are comparable to humans [11]; however, the response in
rodents is more modest than that observed in humans supplemented with AA [11]. Our highest
supplemented dose of 1.35% of energy (or a HED of 3 g/d) increased phospholipid AA levels in
plasma/serum by 40%, while providing a dose of 0.75-1.5 g/d in humans increased tissue AA
content by ~85% [30-31] with a maximum change of 136% at a dose of 6 g/d [32]. Rodents,
compared to humans, have higher requirements for the more highly unsaturated fatty acid DHA
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in their tissue phospholipids [33]. This may preclude the need for higher levels of AA in tissues,
accounting for the more modest effects observed in rodents following AA supplementation. Of
importance, these changes in AA content were always at the expense of tissue LA, suggesting
that dietary AA targets the same phospholipid pool occupied by LA [12, 27-28]. This inverse
relationship between tissue levels of AA and LA following AA supplementation is supported by
human clinical data [30]. The inverse is not always true. While some studies suggest an inverse
relationship exists between tissue LA and AA levels when LA is supplemented in the diet [11,
20, 23], these studies are in the minority.
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Conclusion
Currently there are no guidelines providing assistance as to how to formulate a human
equivalent diet for rodents to improve translation of data to that of humans. The overall objective
of this research was to test a theoretical model for allometric scaling based on energy differences
between species. We chose the relationship between dietary LA and its effects on tissue AA
content as a testable hypothesis. We wanted to determine the extent to which supplementation of
human equivalent doses of LA and AA had on changes in tissue AA content within the context
of a Western-type diet using a common experimental rodent model. We proposed that providing
animals a background diet that mimicked the Western diet with regards to macro- and
micronutrients and fatty acid profiles, and supplementing LA at human equivalent doses, we
could observe a human equivalent response with regard to changes in AA levels in plasma/serum
and erythrocyte phospholipids. Our results recapitulated those in humans and provide support for
the concept that allometric scaling between species for dietary LA can be accomplished based on
energy and metabolic differences. It is important to note that these results cannot be extrapolated
to all tissues.
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Table 4. Composition of the diets
1

2

-2%1
Diet

LA

Control

3

Dietary Groups
4
5
6

7

8

9

+0.45%

+1.36%

+2%

+4%

+6%

+8% +0.23%

LA

LA

LA

LA

AA

AA

AA

g/100g
Protein

17.4

17.4

17.4

17.4

17.4

17.4

17.4

17.4

17.4

Carbohydrate

54.5

54.5

54.5

54.5

54.5

54.5

54.5

54.5

54.5

Lipid

17.1

17.1

17.1

17.1

17.1

17.1

17.1

17.1

17.1

g/kg
Casein

150

150

150

150

150

150

150

150

150

L-Cysteine

3

3

3

3

3

3

3

3

3

Corn Starch

295

295

295

295

295

295

295

295

295

Maltodextrin 10

75

75

75

75

75

75

75

75

75

Sucrose

100

100

100

100

100

100

100

100

100

Cellulose

50

50

50

50

50

50

50

50

50

41.6

37.5

33.3

29.1

25.0

21

36.9

35.9

32.1

Cocoa Butter, Deodorized
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Table 4. Continued
1

2

-2%1
Diet

LA

Control

3

Dietary Groups
4
5
6

7

8

9

+0.45%

+1.36%

AA

AA

AA

+2%

+4%

+6%

+8% +0.23%

LA

LA

LA

LA

g/100g
Flaxseed Oil

4.5

4.5

4.5

4.5

4.5

4.5

4.5

4.5

4.5

Palm Oil, Bleached,
Deodorized
Safflower Oil, USP

58.4

52.5

46.8

41.1

35.3

29.5

52.5

52.5

52.5

15.6

28.5

28.5

28.5

28.5

28.5

28.5

28.5

28.5

30

27

24.1

21.1

18.2

15.2

27

27

27

-

-

12.8

25.7

38.5

51.3

-

-

-

0.35

0.35

0.35

0.35

0.35

0.35

0.97

1.93

5.8

Eicosapentaenoic Acid,
0.15
Ethyl Ester
Docosahexaenoic Acid,
0.24
Ethyl Ester
1
% change with regards to energy

0.15

0.15

0.15

0.15

0.15

0.15

0.15

0.15

0.24

0.24

0.24

0.24

0.24

0.24

0.24

0.24

Trisun Extra
Sunflower Oil
Arachidonic Acid, Ethyl
Ester

Abbreviations: AA, arachidonic acid; LA, linoleic acid
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Table 5. The fatty acid composition of the diets
Dietary Groups
1

2

-2%1

3

4

5

6

7

8

9

2%

4%

6%

8%

0.23%

0.45%

1.36%

Fatty Acids

LA

Control

LA

LA

LA

LA

AA

AA

AA

12:0

0.472

0.42

0.39

0.34

0.27

0.26

0.42

0.43

0.42

14:0

0.69

0.69

0.59

0.56

0.48

0.43

0.63

0.65

0.66

16:0

26.48

24.69

22.66

20.63 18.71

16.8

24.62

24.31

23.71

16:1

0.17

0.1

0.15

0.14

0.09

0.09

0.15

0.16

0.16

18:0

13.13

11.39

11.19

10.08

9.52

8.5

11.69

11.29

10.54

18:1n-9

42.44

40.44

38.44

36.62 35.00

33.06

40.11

39.79

39.00

18:2n-6

13.24

18.93

23.23

28.24

32.5

37.39

19.01

19.05

19.08

18:3n-3

1.78

1.79

1.77

1.8

1.77

1.8

1.78

1.84

1.83

20:0

0.58

0.54

0.52

0.49

0.48

0.44

0.55

0.55

0.51

20:1

0.14

0.17

0.15

0.15

0.17

0.14

0.16

0.17

0.14

20:4n-6

0.21

0.21

0.22

0.22

0.2

0.22

0.55

1.11

3.32
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Table 5. Continued
Dietary Groups
1

2

-2%1

3

4

5

6

7

8

9

2%

4%

6%

8%

0.23%

0.45%

1.36%

Fatty Acids

LA

Control

LA

LA

LA

LA

AA

AA

AA

20:5n-3

0.09

0.03

0.08

0.07

0.06

0.1

0.05

0.09

0.06

22:0

0.31

0.31

0.34

0.37

0.42

0.46

0.31

0.29

0.30

22:6n-3

0.26

0.29

0.27

0.28

0.29

0.31

0.3

0.27

0.27

1

% change with regards to energy

2

g/kg diet

Abbreviations. LA, linoleic acid; AA, arachidonic acid
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Table 6. The fatty acid composition of plasma phospholipids from mice fed linoleic acid supplemented diets
Dietary Groups
Fatty

1

2

3

4

5

6

Acid

-2% LA1

Control

+2% LA

+4% LA

+6% LA

+8% LA

16:0

33.54 ± 0.932

34.40 ± 0.80

33.60 ± 1.03

33.25 ± 0.96

35.29 ± 1.15

32.87 ± 0.88

18:0

13.68 ± 0.55

13.41 ± 0.31

13.07 ± 0.56

13.84 ± 0.61

13.97 ± 0.66

13.49 ± 0.54

18:1n-9

12.50 ± 0.50

11.69 ± 0.65

9.11 ± 0.64

9.23 ± 0.70

10.29 ± 1.26

10.10 ± 1.18

18:2n-6

17.80 ± 0.28a

19.22 ± 0.42ab

20.58 ± 0.44ab

21.86 ± 0.93b

22.15 ± 1.53b

22.46 ± 1.27b

20:4n-6

13.41 ± 0.40

12.74 ± 0.50

13.94 ± 0.84

13.39 ± 0.63

11.77 ± 0.75

13.10 ± 0.63

22:6n-3

9.07 ± 0.98a

8.54 ± 0.56ab

9.09 ± 0.60a

8.43 ± 0.59ab

6.53 ± 0.79b

7.99 ± 0.49ab

1

%change with regards to energy

2

Relative abundance (mol%) presented as mean ± SEM

ab

Means with the same superscript within the same row are not statistically different at p< 0.05, Tukey‟s

honestly significant difference.
Abbreviations: LA, linoleic acid
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Table 7. The fatty acid composition of plasma phospholipids from mice fed arachidonic acid supplemented diets
Dietary Groups
2

7

8

9

Control

+0.23% AA1

+0.45% AA

+1.36% AA

16:0

34.40 ± 0.87²

33.62 ± 0.82

33.71 ± 1.07

34.76 ± 0.81

18:0

13.41 ± 0.34

13.25 ± 0.42

13.34 ± 0.53

12.82 ± 0.36

18:1n-9

11.69 ± 0.72

11.80 ± 0.83

11.69 ± 0.96

11.53 ± 0.94

18:2n-6

19.22 ± 0.46a

18.88 ± 0.59ab

17.04 ± 0.28bc

15.47 ± 0.41c

20:4n-6

12.74 ± 0.54a

14.21 ± 0.66ab

15.94 ± 0.81bc

17.93 ± 1.00c

22:6n-3

8.54 ± 0.55

8.52 ± 0.52

8.28 ± 0.51

7.51 ± 0.45

Fatty Acid

1

%change with regards to energy

2

Relative abundance (mol%) presented as mean ± SEM

abc

Means with the same superscript within the same row are not statistically different at p< 0.05, Tukey‟s

honestly significant difference.
Abbreviations: AA, arachidonic acid
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25.00
ab
a ab

20.00
Mole%

b b b

-2 en% LA
Control

15.00

+2 en% LA

10.00

+4 en% LA
5.00

+6 en% LA

0.00

+8 en% LA
18:1n-9

18:2n-6

20:4n-6

Fatty Acids
Figure 8. Effects of increasing/decreasing dietary linoleic acid on changes in plasma/serum
phospholipid fatty acid concentration. Mice were fed background diets that mimicked the
composition of a Western diet with increasing or decreasing levels (% change, based on energy)
of linoleic acid. The data (mol%) is presented as mean ± SEM. Means with the same superscript
within the same row (i.e., individual fatty acid) are not statistically different at (p<0.05).
Abbreviations: LA, linoleic acid
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a ab

20.00

c

bc

bc

c
a

Mole%

15.00

ab
Control

10.00

+0.23 en%
AA

5.00

+0.45 en%
AA

0.00

+1.36 en%
AA
18:1n-9

18:2n-6
20:4n-6
Fatty Acids

22:6n-3

Figure 9. Effects of increasing dietary arachidonic acid on changes in plasma/serum
phospholipid fatty acid concentration. Mice were fed background diets that mimicked the
composition of a Western diet with increasing levels (% change, based on energy) of arachidonic
acid. The data (mol%) is presented as mean ± SEM. Means with the same superscript within the
same row (i.e., individual fatty acid) are not statistically different at (p<0.05). Abbreviations:
AA, arachidonic acid
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Table 8. The fatty acid composition of erythrocytes phospholipids from diets supplemented with linoleic acid
Dietary Groups
Fatty

1

2

3

4

5

6

Acid

-2% LA1

Control

+2% LA

+4% LA

+6% LA

+8% LA

16:0

34.19 ± 0.66²

34.80 ± 0.63

34.40 ± 0.48

32.81 ± 0.69

34.67 ± 0.62

33.57 ± 0.71

18:0

13.77 ± 0.30

14.09 ± 0.52

15.45 ± 0.43

14.73 ± 0.45

14.18 ± 0.30

15.35 ± 0.57

18:1n-9

17.57 ± 0.40a

16.63 ± 0.46a

14.50 ± 0.34b

14.61 ± 0.21b

14.48 ± 0.28b

14.09 ± 0.31b

18:2n-6

10.69 ± 0.13a

12.03 ± 0.23b

12.23 ± 0.24b

13.09 ± 0.48bc

13.72 ± 0.28cd

14.52 ± 0.12d

20:3n-6

1.18 ± 0.33

1.12 ± 0.04

1.22 ± 0.61

1.19 ± 0.08

1.18 ± 0.03

1.18 ± 0.06

20:4n-6

14.33 ± 0.54

13.60 ± 0.57

14.58 ± 0.45

15.12 ± 0.65

14.56 ± 0.41

13.66 ± 0.74

22:4n-6

1.40 ± 0.05

1.27 ± 0.13

1.44 ± 0.10

1.62 ± 0.13

1.67 ± 0.06

1.51 ± 0.10

22:5n-6

0.40 ± 0.05

0.45 ± 0.02

0.50 ± 0.03

0.58 ± 0.10

0.55 ± 0.02

0.47 ± 0.04

22:5n-3

0.70 ± 0.04

0.64 ± 0.04

0.60 ± 0.03

0.63 ± 0.05

0.60 ± 0.03

0.57 ± 0.05

22:6n-3

5.76 ± 0.34

5.37 ± 0.49

5.43 ± 0.20

5.64 ± 0.36

5.29 ± 0.27

4.99 ± 0.54

1

%change with regards to energy
Relative abundance (mol%) presented as mean ± SEM
abcd
Means with the same superscript within the same row are not statistically different at p< 0.05, Tukey‟s
honestly significant difference.
Abbreviations: LA, linoleic acid
2
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Table 9. The fatty acid composition of erythrocyte phospholipids from diets supplemented with arachidonic acid
Dietary Groups
2
7
8
9

1
2

Fatty Acid

Control

+0.23% AA1

+0.45% AA

+1.36% AA

16:0

34.80 ± 0.69²

34.08 ± 0.86

34.43 ± 0.91

35.17 ± 0.95

18:0

14.09 ± 0.57

14.56 ± 0.31

14.03 ± 0.37

13.95 ± 0.34

18:1n-9

16.64 ± 0.50

16.49 ± 0.15

15.94 ± 0.29

15.62 ± 0.51

18:2n-6

12.03 ± 0.25a

10.85 ± 0.16b

9.65 ± 0.18c

7.84 ± 0.07d

20:3n-6

1.12 ± 0.05a

0.94 ± 0.01b

0.77 ± 0.02c

0.44 ± 0.01d

20:4n-6

13.60 ± 0.63a

15.13 ± 0.52ab

16.77 ± 0.53bc

18.71 ± 0.93c

22:4n-6

1.27 ± 0.15a

1.54 ± 0.09ab

1.90 ± 0.07bc

2.20 ± 0.11c

22:5n-6

0.45 ± 0.03a

0.49 ± 0.02ab

0.57 ± 0.04ab

0.73 ± 0.05c

22:5n-3

0.64 ± 0.06

0.64 ± 0.03

0.65 ± 0.03

0.55 ± 0.04

22:6n-3
5.37 ± 0.54
%change with regards to energy

5.28 ± 0.23

5.29 ± 0.37

4.78 ± 0.40

Relative abundance (mol%) presented as mean ± SEM

abcd

Means with the same superscript within the same row are not statistically different at p< 0.05, Tukey‟s honestly
significant difference.
Abbreviations: AA, arachidonic acid
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a

Control

10.00

+2 en % LA
+4 en% LA

5.00

+6 en% LA
+8 en% LA

0.00
18:1n-9

18:2n-6

20:4n-6

Fatty Acids

Figure 10. Effects of increasing/decreasing dietary linoleic acid on changes in erythrocyte
phospholipid fatty acid concentration. Mice were fed background diets that mimicked the
composition of a Western diet with increasing or decreasing levels (% change, based on energy)
of linoleic acid. The data (mol%) is presented as mean ± SEM. Means with the same superscript
within the same row (i.e., individual fatty acid) are not statistically different at (p<0.05).
Abbreviations: LA, linoleic acid.
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20.00

a

15.00
Mole %

a
10.00

b

ab
ab

c

Control

d
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5.00

+1.36 en% AA
0.00
18:1n-9

18:2n-6

20:4n-6

22:6n-3

Fatty Acids
Figure 11. Effects of increasing dietary arachidonic acid on changes in erythrocyte phospholipid
fatty acid concentration. Mice were fed background diets that mimicked the composition of a
Western diet with increasing levels (% change, based on energy) of arachidonic acid. The data
(mol%) is presented as mean ± SEM. Means with the same superscript within the same row (i.e.,
individual fatty acids) are not statistically different at (p<0.05). Abbreviations: AA, arachidonic
acid.
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“Don’t be afraid, for I am with you. Don’t be discouraged, for I am your
God. I will strengthen you and help you. I will hold you up with my
victorious right hand”

~ Isaiah 41:10
“Hard things are put in our way, not to stop us, but to call out our courage
and strength”

~Unknown Author

“With ordinary talent and extraordinary perseverance, all things are
attainable”

~Thomas Foxwell Buxton
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